Glucose variability: An emerging target for the treatment of diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 102, Issue 2, 2013, Pages 86-95

  Frontoni, Simona ^a   Di Bartolo, Paolo ^b   Avogaro, Angelo ^c   Bosi, Emanuele ^d   Paolisso, Giuseppe ^e   Ceriello, Antonio ^f  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UO Diabetologia   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Diabetic complications; Glucose variability; Treatment

Indexed keywords

GLUCOSE;

AREA UNDER THE CURVE; AVERAGE DAILY RISK RANGE; BLOOD GLUCOSE MONITORING; BLOOD GLUCOSE RISK INDEX; COEFFICIENT OF VARIATION; CONSTANTS AND COEFFICIENTS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE VARIABILITY; HIGH BLOOD GLUCOSE INDEX; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE; LOW BLOOD GLUCOSE INDEX; MEDICAL PARAMETERS; METABOLIC PARAMETERS; OXIDATIVE STRESS; POSTPRANDIAL STATE; REVIEW; TREATMENT PLANNING; YOUDEN INDEX;

DIABETIC COMPLICATIONS; GLUCOSE VARIABILITY; TREATMENT;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84888432834     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.09.007     Document Type: Review

References (92)

1. Green C.B., Takahashi J.S., Bass J. The meter of metabolism. Cell 2008, 134:728-742.
2. Konsaka A., Bass J. A sense of time: how molecular clocks organize metabolism. Trends Endocrinol Metab 2007, 18:4-11.
3. Buijs R.M., Kreier F. The metabolic syndrome: a brain disease?. J Neuroendocrinol 2006, 18:715-716.
4. Staels B. When the Clock stops ticking, metabolic syndrome explodes. Nat Med 2006, 12:54-55.
5. Velasco A., Huerta I., Marin B. Plasma corticosterone, motor activity and metabolic circadian patterns in streptozotocin-induced diabetic rats. Chronobiol Int 1988, 5:127-135.
6. Shimomura Y., Takahashi M., Shimizu H., Sato N., Uehara Y., Negishi M.I., et al. Abnormal feeding behavior and insulin replacement in STZ-induced diabetic rats. Physiol Behav 1990, 47:731-734.
7. Van Cauter E., Polonsky K.S., Scheen A.J. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev 1997, 18:716-738.
8. Spallone V., Bernardi L., Ricordi L., Soldà P., Maiello M.R., Calciati A., et al. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993, 42:1745-1752.
9. Boden G., Chen X., Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 1999, 48:2182-2188.
10. Wang C., Lv L., Yang Y., Chen D., Liu G., Chen L., et al. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly-diagnosed type 2 diabetes mellitus. Clin Endocrinol 2012, 6:810-815.
11. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23:45-50.
12. Siegelaar S.E., Kerr L., Jacober S.J., Devries J.H. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011, 34:855-857.
13. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
14. Lachin J.M., Genuth S., Nathan D.M., Zinman B., Rutledge B.N. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial revisited. Diabetes 2008, 57:995-1001.
15. Nalysnyk L., Hernandez-Medina M., Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010, 12:288-298.
16. Sartore G., Chilelli N.C., Burlina S., Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol 2013, 50:437-442.
17. Waden J., Forsblom C., Thorn L.M., Gordin D., Saraheimo M., Groop P.H. Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009, 58:2649-2655.
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
19. Picconi F., Di Flaviani A., Malandrucco I., Giordani I., Frontoni S. Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. Nutr Metab Cardiovasc Dis 2012, 22:691-696.
20. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009, 11:551-565.
21. Weber C., Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009, 11:623-633.
22. Standl E., Schnell O., Ceriello A. Postprandial hyperglycemia and glycemic variability. Should we care?. Diabetes Care 2011, (Suppl. 2):S120-S127.
23. Kim H.S., Shin J.A., Chang J.S., Cho J.H., Son H.Y., Yoon K.H. Continuous glucose monitoring: current clinical use. Diabetes Metab Res Rev 2012, 28(Suppl. 2):73-78.
24. Mosca A., Lapolla A., Gillery P. Glycemic control in the clinical management of diabetic patients. Clin Chem Lab Med 2012, 8:1-14.
25. Kuenen J.C., Borg R., Kuik D.J., Zheng H., Schoenfeld D., Diamant M., et al. Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients?. Diabetes Care 2011, 34:1843-1847.
26. Rodbard D., Glycemic Variability: Measurement and utility in clinical medicine and research-one viewpoint. Diabetes Technol Ther 2011, 13:1-4.
27. Hirsch I.B., Parkin C.G. Is A1c the best measure of glycemic control? 2005, 1-5. Business Briefing: US Endocrine Review.
28. Hinzmann R., Schlaeger C., Tran C.T. What do we need beyond hemoglobin A1c to get the complete picture of glycemia in people with diabetes?. Int J Med Sci 2012, 9(8):665-681.
29. Wójcicki J.M. "J"-index: a new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995, 27:41-42.
30. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
31. McDonnell C.M., Donath S.M., Vidmar S.I., Werther G.A., Cameron F.J. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005, 7:253-263.
32. Kovatchev B.P., Clarke W.L., Breton M., Brayman K., McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005, 7:849-862.
33. Kovatchev B.P., Cox D.J., Kumar A., Gonder-Frederick L., Clarke W.L. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003, 5:817-828.
34. Kovatchev B.P., Otto E., Cox D., Gonder-Frederick L., Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006, 29:2433-2438.
35. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009, 11(Suppl. 1):S55-S67.
36. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
37. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
38. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med 2008, 359:1565-1576.
39. Brownlee M., Hirsch I.B. Glycemic variability: a hemoglobin A1c independent risk factor for diabetic complications. J Am Med Assoc 2006, 295:1707-1782.
40. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7.
41. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
42. Raz I., Wilson P.W., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32:381-386.
43. Deedwania P., Kosiborod M., Barrett E., Ceriello A., Isley W., Mazzone T., et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008, 117:1610-1619.
44. Langouche L., Vanhorebeek I., Van den Berghe G. Therapy insight: the effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 2007, 3:270-278.
45. Salardi S., Zucchini S., Santoni R., Ragni L., Gualandi S., Cicognani A., et al. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbAlc in pediatric type 1 diabetic patients. Diabetes Care 2002, 25:1840-1844.
46. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006, 29:1486-1490.
47. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009, 32:1901-1903.
48. Kilpatrick E.S., Rigby A.S., Atkin S.L. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008, 51:365-371.
49. Kilpatrick E.S., Rigby A.S., Atkin S.L. A1c variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008, 31:2198-2202.
50. Bragd J., Adamson U., Bäcklund L.B., Lins P.E., Moberg E., Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diabetes Metab 2008, 34:612-616.
51. Muggeo M., Verlato G., Bonora E., Zoppini G., Corbellini M., de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with noninsulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997, 96:1750-1754.
52. Egi M., Bellomo R., Stachowski E., French C.J., Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006, 105:244-252.
53. Krinsley J.S. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008, 36:3008-3013.
54. Finfer S., Chittock D.R., Su S.Y., Blair D., Foster D., Dhingra V., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297.
55. Kosiborod M., Inzucchi S.E., Goyal A., Krumholz H.M., Masoudi F.A., Xiao L., et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. J Am Med Assoc 2009, 301:1556-1564.
56. Kosiborod M., Inzucchi S.E., Krumholz H.M., Masoudi F.A., Goyal A., Xiao L., et al. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med 2009, 169:438-446.
57. Nerenberg K.A., Goyal A., Xavier D., Sigamani A., Ng J., Mehta S.R., et al. Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial. Diabetes Care 2012, 35:19-24.
58. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
59. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
60. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 571349-571354.
61. Di Flaviani A., Picconi F., Di Stefano P., Giordani I., Malandrucco I., Maggio P., et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 2011, 34:1605-1609.
62. Monnier L., Colette C., Mas E., Michel F., Cristol J.P., Boegner C., et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010, 53:562-571.
63. Wentholt I.M., Kulik W., Michels R.P., Hoekstra J.B., DeVries J.H. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008, 51:183-190.
64. Ihnat M.A., Thorpe J.E., Kamat C.D., Piconi L., Kaltreider R.C., Cariello A. Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose. Am J Biochem Biotechnol 2007, 3:16-23.
65. Ceriello A., Morocutti A., Mercuri F., Quagliaro L., Moro M., Damante G., et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000, 49:2170-2177.
66. Hodgkinson A.D., Bartlett T., Oates P.J., Millward B.A., Demaine A.G. The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes 2003, 52:846-851.
67. Meugnier E., Faraj M., Rome S., Beauregard G., Michaut A., Pelloux V., et al. Acute hyperglycemia induces a global down-regulation of gene expression in adipose tissue and skeletal muscle of healthy subjects. Diabetes 2007, 56:992-999.
68. Schisano B., Tripathi G., McGee K., McTernan P.G., Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011, 54:1219-1226.
69. De Natale C., Annuzzi G., Bozzetto L., Mazzarella R., Costabile G., Ciano O., et al. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care 2009, 32:2168-2173.
70. Riccardi G., Rivellese AA: Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care 1991, 14:1115-1125.
71. McCulloch D.K., Kurtz A.B., Tattersall R.B. A new approach to the treatment of nocturnal hypoglycaemia using alpha glucosidase inhibition. Diabetes Care 1983, 6:483-487.
72. Shimbakuro M., Higa N., Chinen I., Yamakawa K., Takasu N. Effects of a single administration of acarbose on post-prandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized cross-over study. J Clin Endocrinol Metab 2006, 91:837-842.
73. Rosak C., Haupt E., Walter T., Werner J. The effect of combination treatment with acarbose and glibenclamide on post-prandial glucose and insulin profile. Additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab 2002, 15:143-151.
74. Bao Y.Q., Zhou J., Zhou M., Cheng Y.J., Lu W., Pan X.P., et al. Glipizide controlled release tablets, with or without acarbose, improve glycaemic variability in new diagnosed type 2 diabetes. Clin Exp Pharmacol Physiol 2010, 37:564-568.
75. Marfella R., Barbieri M., Grella R., Rizzo M.R., Nicoletti G.F., Paolisso G. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-h acute glucose fluctuations. J Diabetes Complications 2010, 24:79-83.
76. Rizzo M.R., Barbieri M., Marfella R., Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012, 35(10):2076-2082.
77. Potashman M.H., Duggan M.E. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 2009, 52:1231-1246.
78. Baetta R., Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011, 71:1441-1467.
79. Barbieri M., Rizzo M.R., Marfella R., Boccardi V., Esposito A., Pansini A., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013, 227:349-354.
80. Shyangdan D.S., Royle P., Clar C., Sharma P., Waugh N., Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, 10:CD006423.
81. Mori Y., Taniguchi Y., Sezaki K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diabetes Technol Ther 2011, 13:1139-1144.
82. Irace C., Fiorentino R., Carallo C., Scavelli F., Gnasso A. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. Diabetes Technol Ther 2011, 13:1261-1263.
83. Anderson J.H., Brunelle R.L., Koivisto V.A., Pfützner A., Trautmann M.E., Vignati L., et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997, 46:265-270.
84. Anderson J.H., Brunelle R.L., Keohane P., Koivisto V.A., Trautmann M.E., Vignati L., et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997, 157:1249-1255.
85. Perriello G., Pampanelli S., Porcellati F., Avogaro A., Bosi E., Petrella G., et al. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabetes Med 2005, 22:606-611.
86. Bolli G.B., Songini M., Trovati M., Del Prato S., Ghirlanda G., Cordera R., et al. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis 2009, 19:571-579.
87. Birkeland K.I., Home P.D., Wendisch U., Ratner R.E., Johansen T., Endahl L.A., et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34:661-665.
88. Heise T., Tack C.J., Cuddihy R., Davidson J., Gouet D., Liebl A., et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011, 34:669-674.
89. Slover R.H., Welsh J.B., Criego A., Weinzimer S.A., Willi S.M., Wood M.A., et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes 2012, 13:6-11.
90. Klupa T., Benbenek-Klupa T., Malecki M., Szalecki M., Sieradzki J. Clinical usefulness of a bolus calculator in maintaining normoglycaemia in active professional patients with type 1diabetes treated with continuous subcutaneous insulin infusion. J Int Med Res 2008, 36:1112-1116.
91. Rossi M.C., Nicolucci A., Pellegrini F., Bruttomesso D., Di Bartolo P.D., Marelli G., et al. Interactive diary for diabetes: a useful and easy-to-use new telemedicine system to support the decision-making process in type 1 diabetes. Diabetes Technol Ther 2009, 11:19-24.
92. Polonsky W.H., Fisher L., Schikman C.H., Hinnen D.A., Parkin C.G., Jelsovsky Z., et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011, 34:262-267.